Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


J&J, Hacker Work Together To Fix Insulin Pump Vulnerability

Executive Summary

US FDA says the collaborative approach taken by an independent security researcher and Johnson & Johnson/Animas in responding to a potentially fatal cybersecurity vulnerability with the firm's Animas OneTouch Ping insulin pump should be a model for the industry that aligns with the agency's recent draft guidance.


Related Content

US Homeland Security Sees Rapid Growth In Device Cybersecurity Vulnerability Reports
Digital Health, Cybersecurity Would See Significant Chunk Of FDA Device-Funding Boost
Multiple Hacking Risks Found In Another Infusion Pump
Feds Holding Workshop on Medical Device Cybersecurity Gaps
Device-Makers Have Amped Up Defenses Against Hackers
Lawmakers Question FDA On Medical Device Cybersecurity Concerns
St. Jude Hacking-Risk Allegations: US FDA Continues Assessment, As Firm Files Lawsuit
St. Jude, Short-Seller Wrestle Over Alleged Security Vulnerabilities
Companies Nervous About 'Sharing' Organizations Touted In FDA Cyber Guidance


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts